Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic. Inrebic (fedratinib) is one of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback